LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Search

Revvity Inc

Suletud

SektorTervishoid

96.73 -0.2

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

95.65

Max

97

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

50.397

78.892

Aktsiakasum

0.4

Dividenditootlus

0.29

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+14.92% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.29%

2.38%

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

71M

11B

Eelmine avamishind

96.93

Eelmine sulgemishind

96.73

Uudiste sentiment

By Acuity

40%

60%

124 / 374 Pingereas Healthcare

Revvity Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. dets 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26. dets 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26. dets 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26. dets 2025, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26. dets 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26. dets 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26. dets 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26. dets 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26. dets 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26. dets 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26. dets 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26. dets 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26. dets 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26. dets 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26. dets 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26. dets 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25. dets 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. dets 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. dets 2025, 00:20 UTC

Omandamised, ülevõtmised, äriostud

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. dets 2025, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24. dets 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. dets 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24. dets 2025, 19:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

24. dets 2025, 19:09 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24. dets 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Revvity Inc Prognoos

Hinnasiht

By TipRanks

14.92% tõus

12 kuu keskmine prognoos

Keskmine 111.22 USD  14.92%

Kõrge 123 USD

Madal 100 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Revvity Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

10 ratings

5

Osta

5

Hoia

0

Müü

Sentiment

By Acuity

124 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat